These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 26470647)

  • 1. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial.
    Haude M; Ince H; Abizaid A; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Kaiser C; Eeckhout E; Lim ST; Escaned J; Garcia-Garcia HM; Waksman R
    Lancet; 2016 Jan; 387(10013):31-9. PubMed ID: 26470647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.
    Haude M; Erbel R; Erne P; Verheye S; Degen H; Böse D; Vermeersch P; Wijnbergen I; Weissman N; Prati F; Waksman R; Koolen J
    Lancet; 2013 Mar; 381(9869):836-44. PubMed ID: 23332165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial.
    Haude M; Ince H; Abizaid A; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Kaiser C; Eeckhout E; Lim ST; Escaned J; Onuma Y; Garcia-Garcia HM; Waksman R
    Eur Heart J; 2016 Sep; 37(35):2701-9. PubMed ID: 27190094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
    Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
    Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.
    Haude M; Erbel R; Erne P; Verheye S; Degen H; Vermeersch P; Weissman N; Prati F; Bruining N; Waksman R; Koolen J
    EuroIntervention; 2016 Jun; 12(2):e160-6. PubMed ID: 27290675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
    Serruys PW; Onuma Y; Ormiston JA; de Bruyne B; Regar E; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Miquel-Hebert K; Rapoza R; García-García HM
    Circulation; 2010 Nov; 122(22):2301-12. PubMed ID: 21098436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
    Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A
    JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris - DREAMS 2G) in de novo coronary lesions: Insights from the BIOSOLVE-II First-In-Man Trial.
    Garcia-Garcia HM; Haude M; Kuku K; Hideo-Kajita A; Ince H; Abizaid A; Tölg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Escaned J; Dijkstra J; Waksman R
    Int J Cardiol; 2018 Mar; 255():22-28. PubMed ID: 29292064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo coronary lesions: three-year clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial.
    Haude M; Ince H; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Eeckhout E; Garcia-Garcia HM; Waksman R
    EuroIntervention; 2020 Feb; 15(15):e1375-e1382. PubMed ID: 30803936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: Pooled 12-month outcomes of BIOSOLVE-II and BIOSOLVE-III.
    Haude M; Ince H; Kische S; Abizaid A; Tölg R; Alves Lemos P; Van Mieghem NM; Verheye S; von Birgelen C; Christiansen EH; Barbato E; Garcia-Garcia HM; Waksman R;
    Catheter Cardiovasc Interv; 2018 Dec; 92(7):E502-E511. PubMed ID: 30079472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
    Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB;
    EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and multimodality imaging results at 6 months of a bioresorbable sirolimus-eluting scaffold for patients with single de novo coronary artery lesions: the NeoVas first-in-man trial.
    Zhang YJ; Wang XZ; Fu G; Jing QM; Wang G; Jin CY; Xie LH; Cai JZ; Xu B; Han YL
    EuroIntervention; 2016 Nov; 12(10):1279-1287. PubMed ID: 27866137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicenter BIOMAG-I first-in-human study.
    Haude M; Wlodarczak A; van der Schaaf RJ; Torzewski J; Ferdinande B; Escaned J; Iglesias JF; Bennett J; Toth G; Joner M; Toelg R; Wiemer M; Olivecrona G; Vermeersch P; Garcia-Garcia HM; Waksman R
    EClinicalMedicine; 2023 May; 59():101940. PubMed ID: 37113674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
    Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A first-in-man clinical evaluation of Ultimaster, a new drug-eluting coronary stent system: CENTURY study.
    Barbato E; Salinger-Martinovic S; Sagic D; Beleslin B; Vrolix M; Neskovic AN; Jagic N; Verheye S; Mehmedbegovic Z; Wijns W
    EuroIntervention; 2015 Sep; 11(5):541-8. PubMed ID: 25136883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-in-man study evaluating the safety and efficacy of a second generation biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo coronary lesions: clinical, Angiographic, and OCT outcomes of CREDIT-1.
    Wang G; Sun Z; Jin Q; Xu K; Li Y; Wang X; Ma Y; Liu H; Zhao X; Wang B; Deng J; Guan S; Ge M; Wang X; Xu B; Han Y
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():744-51. PubMed ID: 25630447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained Safety and Performance of the Second-Generation Sirolimus-Eluting Absorbable Metal Scaffold: Pooled Outcomes of the BIOSOLVE-II and -III Trials at 3 Years.
    Haude M; Ince H; Kische S; Toelg R; Van Mieghem NM; Verheye S; von Birgelen C; Christiansen EH; Barbato E; Garcia-Garcia HM; Waksman R
    Cardiovasc Revasc Med; 2020 Sep; 21(9):1150-1154. PubMed ID: 32917533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
    Serruys PW; Chevalier B; Sotomi Y; Cequier A; Carrié D; Piek JJ; Van Boven AJ; Dominici M; Dudek D; McClean D; Helqvist S; Haude M; Reith S; de Sousa Almeida M; Campo G; Iñiguez A; Sabaté M; Windecker S; Onuma Y
    Lancet; 2016 Nov; 388(10059):2479-2491. PubMed ID: 27806897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III.
    Haude M; Ince H; Kische S; Abizaid A; Tölg R; Alves Lemos P; Van Mieghem NM; Verheye S; von Birgelen C; Christiansen EH; Wijns W; Garcia-Garcia HM; Waksman R
    EuroIntervention; 2017 Jul; 13(4):432-439. PubMed ID: 28504239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.